Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats

Nephrology Dialysis Transplantation

Volumn 25, Issue 2, 2010, Pages 389-399

  Chung, Sungjin ^a   Park, Cheol Whee ^a   Shin, Seok Joon ^a   Lim, Ji Hee ^a   Chung, Hyun Wha ^a   Youn, Dong Ye ^b   Kim, Hyung Wook ^a   Kim, Byung Soo ^a   Lee, Jeong Hwa ^b   Kim, Gheun Ho ^c   Chang, Yoon Sik ^a  

^a Division of Nephrology   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Hypertension; Lipotoxicity; Obesity; Oxidative stress; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CANDESARTAN HEXETIL; MESSENGER RNA; RENIN; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; KIDNEY CORTEX; KIDNEY INJURY; LIPID DIET; LIPID STORAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

EID: 75649145898     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp472     Document Type: Article

References (54)

1. Dandona P, Aljada A, Chaudhuri A et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
3. Rahmouni K, Correia ML, Haynes WG et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9-14
4. Kannel WB, Garrison RJ, Dannenberg AL. Secular blood pressure trends in normotensive persons: the Framingham Study. Am Heart J 1993; 125: 1154-1158
5. Aneja A, El-Atat F, McFarlane SI et al. Hypertension and obesity. Recent Prog Horm Res 2004; 59: 169-205
6. Knight SF, Quigley JE, Yuan J et al. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension 2008; 51: 352-359
7. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 2004; 15: 2775-2791
8. Kramer H, Luke A, Bidani A et al. Obesity and prevalent and incident CKD: the hypertension detection and follow-up program. Am J Kidney Dis 2005; 46: 587-594
9. Rocchini AP. Obesity hypertension. Am J Hypertens 2002; 15: 50S-52S
10. Sarafidis PA, Bakris GL. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens 2007; 21: 12-19
11. Dandona P, Mohanty P, Ghanim H et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001; 86: 355-362
12. Lin KY, Ito A, Asagami T et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992
13. Weinberg JM. Lipotoxicity. Kidney Int 2006; 70: 1560-1566
14. Hall JE, Brands MW, Henegar JR et al. Abnormal kidney function as a cause anda consequence of obesity hypertension.Clin Exp Pharmacol Physiol 1998; 25: 58-64
15. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281-287
16. El-Atat FA, Stas SN, McFarlane SI et al. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004; 15: 2816-2827
17. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
18. Park CW, Zhang Y, Zhang X et al. PPARα agonist fenofibrate improves diabetic nephropathyindb/db mice.Kidney Int 2006; 69: 1511-1517
19. Park CW, Kim HW, Ko SH et al. Accelerated diabetic nephropa-thy in mice lacking the peroxisome proliferator-activated receptor α. Diabetes 2006; 55: 885-893
20. Park CW, Kim HW, Ko SH et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238
21. Delaney B, Nicolosi RJ, Wilson TA et al. Beta-glucan fractions from barley and oats are similarly antiatherogenic in hypercholesterolemic Syrian golden hamsters. J Nutr 2003; 133: 468-475
22. Hartner A, Porst M, Klanke B et al. Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats. Nephrol Dial Transplant 2006; 21: 1778-1785
23. Knight SF, Quigley JE, Yuan J et al. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension 2008; 51; 352-359
24. Sevoda L, Berude J, Gudet D et al. Diet-induced obesity delays cardiovascular recovery from stress in spontaneously hypertensive rats. Obes Res 2004; 12; 1951-1958
25. Boustany CM, Bharadwaj K, Daugherty A et al. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004; 287: R943-R949
26. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sci 2001; 321: 242-248
27. Licata G, Scaglione R, Ganguzza A et al. Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 1994; 7: 314-320
28. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994; 7: 886-893
29. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998; 24: 789-796
30. El-Gharbawy AH, Nadig VS, Kotchen JM et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001; 37: 845-850
31. Goodfriend TL, Kelley DE, Goodpaster BH et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999; 7: 355-362
32. Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR. Mineralocorticoid-stimulating activity of adipose tissue. Best Pract Res Clin Endocrinol Metab 2005; 19: 567-575
33. Darimont C, Vassaux G, Ailhaud G et al. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinol 1994; 135: 2030-2036
34. Navar LG. The intrarenal renin-angiotensin system in hypertension. Kidney Int 2004; 65: 1522-1532
35. Montani JP, Carroll JF, Dwyer TM et al. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord 2004; 28: S58-S65
36. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004; 24: 366-378
37. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl 1998; 68: S14-S19 (Pubitemid 28531769)
38. Fortepiani LA, Reckelhoff JF. Increasing oxidative stress with mol-sidomine increases blood pressure in genetically hypertensive rats but not normotensive controls. Am J Physiol Regul Integr Comp Physiol 2005; 289: R763-R770
39. Rincon-Choles H, Kasinath BS, Gorin Y et al. Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl 2002; 82: S8-S11
40. Cattaneo D, Remuzzi G. Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. J Ren Nutr 2005; 15: 71-76
41. Zhou YT, Grayburn P, Karim A et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97: 1784-1789
42. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmis-artan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002
43. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44: 12-19
44. Meyer TW. Immunosuppression for diabetic glomerular disease? Kidney Int 2003; 63: 377-378
45. Saraheimo M, Teppo AM, Forsblom C et al. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 2003; 46: 1402-1407 (Pubitemid 37297211)
46. Iglesias-De La Cruz MC, Ruiz-Torres P et al. Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells. Kidney Int 2001; 59: 87-95
47. Jiang Z, Seo JY, Ha H et al. Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun 2003; 309: 961-966
48. Dobrian AD, Davies MJ, Prewitt RL et al. Development of hypertension in a rat model of diet-induced obesity. Hypertension 2000; 35: 1009-1015
49. Yu SM, Huang ZS, Wang CY et al. Effects of hyperlipidemia on the vascular reactivity in the Wistar-Kyoto and spontaneously hypertensive rats. Eur J Pharmacol 1993; 248: 289-295
50. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardio 1999; 83: 25F-29F
51. Weidmann P, Böhlen L, de Courten M. Insulin resistance and hy-perinsulinemia in hypertension. J Hypertens Suppl 1995; 13: S65-S72
52. Andronico G, Cottone S, Mangano MT et al. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 2001; 25: 239-242
53. Wang Y, Wang PY, Qin LQ et al. The development of diabetes mel-litus in Wistar rats kept on a high-fat/low-carbohydrate diet for long periods. Endocrine 2003; 22: 85-92
54. Biswas SK, de Faria JB. Which comes first: renal inflammation or oxidative stress in spontaneously hypertensive rats? Free Radic Res 2007; 41: 216-224